Capital allocation framework — POET Technologies
Executive summary — the inverse of MRVL
Where Marvell operates an “FCF-funded buyback + opportunistic refinancing” capital-return framework returning ~$1.26B/year to shareholders, POET Technologies is on the opposite end of the spectrum:
- No dividend. POET has never paid a dividend in its 18-year listed history. The 20-F does not disclose any near-term plan or board authorization. ✓
- No share buyback. POET has never operated a buyback program and has no authorization on the books. ✓
- No public debt. POET has no senior notes, no credit-facility drawn balance, no secured borrowings beyond a $5.8M convertible note (held by an unaffiliated holder per 20-F note disclosure). ✓
- Capital allocation is a one-way flow: raised equity → R&D + SG&A + working capital + ST investments → consumed. Cumulative shareholder returns to date: $0.
This file therefore replaces the standard “capital returns” framework with a capital allocation framework — what raised capital is spent on, at what burn rate, and what the implied cost of capital is from the equity-raise schedule.
Confidence: ✓ FY2025 20-F audited statements; complete review of POET filing record on SEC EDGAR confirms zero dividend / buyback / debt-issuance history.
1. Dividend program — none
| Item | Status |
|---|---|
| Dividend program | None ✓ |
| Latest disclosed authorization | None ✓ |
| Stated policy in 20-F | ”We have not paid any dividends since incorporation. We currently anticipate that we will retain any future earnings to support operations…” ⚠ paraphrased |
| Board / proxy commentary | No dividend-policy commitments in disclosed proxy materials ⚠ |
| Forward-looking probability | Effectively zero pre-revenue-ramp; reconsideration would require multi-year operating-cash-flow positivity that is not in current management framework ⚠ |
2. Share buyback — none
| Item | Status |
|---|---|
| Buyback authorization | None ✓ |
| Open-market repurchase program | None ✓ |
| Cumulative buyback spend | $0 ✓ |
| Stated framework | None — POET is in capital-raising mode, not capital-return mode |
| Forward-looking probability | Effectively zero — POET has issued ~$430M of fresh equity over the past 14 months; the directional contradiction with a buyback would be acute ⚠ |
Bear-case anchoring. If POET were operationally close to commercial inflection, the most expressive counter-signal would be management ceasing dilution rather than buying shares back. Continued raises (latest: Jan 23 2026) signal that management does not yet view its own equity as the highest-return capital deployment.
3. Public debt — none
POET’s capital stack is 100% equity (common shares, options, warrants) plus a single $5.8M convertible note (current liability per holder conversion right; 4-year scheduled paydown). There is:
- Zero issued senior notes — no fixed-income market readout exists for POET credit.
- Zero drawn revolving credit facility — no signed credit agreement disclosed in the 20-F.
- Zero institutional bank debt — POET is entirely shareholder-equity financed.
See credit_market_positioning for the full “no public debt” framing including the implied cost-of-capital from the equity raise schedule.
4. Where the raised capital actually goes — capital allocation framework
Cash-flow walkforward: where 2025’s $292M of financing went
| FY2025 cash-flow line | $ | What it represents |
|---|---|---|
| Net cash from financing activities | $292,274,542 ✓ | Five raises during 2025 (May, Jul, Oct, Oct — see recent_capital_raises) |
| − Net cash used in operating activities | $(31,086,629) ✓ | $2.6M/month operating burn (incl. SG&A + R&D ex-non-cash) |
| − Net cash used in investing activities | $(259,170,200) ✓ | Dominated by purchases of short-term investments, not capex / M&A |
| + FX effect | $813,699 | Translation gains |
| = Δ cash position FY2025 | +$2,831,412 | Cash on hand effectively flat; the deployment was into ST investments |
| Reconciling: Cash + ST investments YE 2024 → YE 2025 | $53.8M → $313.4M | +$259.6M increase, consistent with $292M raised − $31M operating burn |
The $259M of “investing activities” outflow is almost entirely a redeployment of newly-raised cash into interest-earning short-term investments (T-bills, money-market, short-duration treasuries) — not capex or M&A. POET’s actual capex / IP investment is small (P&E and intangibles combined ~$13M book value, per balance_sheet).
How the operating burn breaks down (FY2025)
| Component | $ | % of opex |
|---|---|---|
| Selling, marketing & administration | $25,081,957 ✓ | 58% |
| · of which: stock-based compensation | $3,890,138 | 9% of total opex |
| · of which: depreciation & amortization | $3,315,899 | 8% of total opex |
| · cash SG&A (residual) | ~$17.9M | 41% |
| Research & development | $18,084,303 ✓ | 42% |
| · of which: stock-based compensation | $2,216,914 | 5% of total opex |
| · cash R&D (residual) | ~$15.9M | 37% |
| Total operating expenses | $43,166,260 | 100% |
| Of which: cash component | ~$33.8M | 78% |
| Of which: non-cash (SBC + D&A) | ~$9.4M | 22% |
Cash burn proxy. ~$33.8M of cash operating spend — close to but slightly higher than the cash-flow-statement “$31.1M used in operating activities” (difference is working-capital movements). This is the cleanest single FY-2025 burn-rate number.
What the FY2026 spend goes toward (per 20-F R&D narrative)
The 20-F R&D narrative is explicit:
“Our focus for 2026 is to develop for sale Optical Engines for 1.6Tbs optical modules and to produce Light Source products incorporating our proprietary hybrid laser, which we have named the Blazar.” ✓ (paraphrase, 20-F R&D section)
Capital-allocation expectations 2026 (analyst extrapolation):
| Spend bucket | FY2025 actual | FY2026 expected ⚠ | Driver |
|---|---|---|---|
| R&D | $18.1M | $22–25M ⚠ | 1.6T Optical Engine productization; Blazar Light Source ramp; foundry NRE / mask costs |
| SG&A (cash) | ~$17.9M | $18–20M ⚠ | Modest growth; FPI / NASDAQ compliance fixed; sales / marketing expansion |
| SBC + D&A (non-cash) | $9.4M | $11–13M ⚠ | Headcount-driven SBC growth; depreciation on incremental P&E |
| Total opex | $43.2M | $50–55M ⚠ | Step-up consistent with R&D narrative |
| Capex (P&E additions) | small (<$2M est.) ⚠ | $3–5M ⚠ | Possible investment in Singapore / Malaysia operations |
| Net cash burn (operating + capex) | ~$33M | ~$45M ⚠ | Annualized “true” cash erosion |
Implication for runway. ~$440M cash post-Jan 2026 raise / ~$45M annualized cash burn = ~10 years of runway absent further raises. That is not a binding constraint. The binding question is whether the per-share value compounds in the absence of meaningful revenue while the company keeps raising at progressively higher prices (and warrants keep getting issued and exercising).
5. Implied cost of capital from the raise schedule (the closest market readout)
Because POET has no public debt, the standard “WACC = blend of bond yield + equity cost” reconciliation is unavailable. The closest market-implied cost-of-capital signal is the average price per share at which POET successfully raised equity vs. the spot price.
| Raise | Date | Price per share / unit | Spot price at raise (close, prior trading day est.) ⚠ | Implied “raise discount” |
|---|---|---|---|---|
| Non-brokered PIPE | 2025-05-22 | $5.00/unit (incl. 1 warrant @ $6.00) | ~$5–6 ⚠ | At-market or discount; warrant attached |
| Non-brokered PIPE | 2025-07-17 | $5.00/unit (incl. 1 warrant @ $6.00) | ~$5.5–6 ⚠ | At-market or discount; warrant attached |
| Non-brokered PIPE | 2025-10-07 | $5.50/unit (incl. ~0.37× warrant @ $7.03) | ~$6–7 ⚠ | Discount; warrant attached |
| Registered direct | 2025-10-28 | $7.25/share (no warrant) | ~$7.5–8 ⚠ | ~3–9% discount; institutional-grade |
| Registered direct | 2026-01-23 | $7.25/share (no warrant) | ~$8.5–9 ⚠ | ~15–20% discount; institutional-grade |
| Wtd avg raise price (all 5 raises 2025–Jan 2026) | ~$6.50/share ⚠ |
Spot 2026-04-28: $8.03. Wtd avg raise price ~$6.50 vs. spot $8.03 = ~19% spot premium to average raise price.
Interpretation. POET has been able to raise at progressively higher prices ($5.00 → $5.50 → $7.25), and the most recent two raises were registered direct (institutional-grade, no Canadian-style warrant attachment). This is consistent with a re-rating of equity-investor confidence over 2025. Bull-side framing: the warrant-free raise structure shows POET no longer needs to bribe with warrant coverage. Bear-side framing: the cumulative dilution is now a structural valuation drag — warrant overhang of 37.4M shares (~28.4% incremental dilution if all exercise) caps near-term per-share appreciation regardless of business progress.
6. Forward capital-allocation framework
POET has not articulated an explicit capital-allocation framework in disclosed materials. From the filing pattern, the de facto framework is:
- Maintain shelf access. F-3ASR primary shelf was refreshed January 22, 2026 (acc. 0001493152-26-003188) and remains open and unrestricted.
- Take down opportunistically on stock-price strength. All five 2025–2026 raises priced at progressively higher prints, suggesting a willingness to time the market rather than draw the shelf on a fixed cadence.
- Match raise size to strategic milestones. $30M (May 2025) → $25M (Jul 2025) → $75M + $150M (Oct 2025) → $150M (Jan 2026) — the larger raises clustered around the announced 1.6T productization roadmap and Q3/Q4 2025 design-win cadence.
- No buyback / dividend layer. All capital flows to R&D, SG&A, working-capital, and ST-investment redeployment — never returned to shareholders.
Forward-looking probability of further raises (analyst estimate ⚠):
- Probability of additional 2026 raise: high if stock price holds >$8 — shelf is open.
- Probability of dividend introduction by 2027: near-zero — operating cash-flow positive is not in management’s stated horizon.
- Probability of buyback authorization by 2027: near-zero — would be directionally inconsistent with continued raises.
Sources
- POET 20-F FY2025 (acc. 0001493152-26-014253, filed 2026-03-31) — primary source for cash-flow / capital-structure narrative.
- POET 424B5 — Jan 2026 $150M RD (acc. 0001493152-26-003330, 2026-01-23).
- POET F-3ASR — primary shelf (acc. 0001493152-26-003188, 2026-01-22).
Cross-references
- Recent capital raises — full chronological raise log
- Balance sheet — pro-forma post Jan 2026 raise
- Quarterly trend — operating burn breakdown
- Credit market positioning — explicit “no-debt” framing
- Share count progression — quarter-by-quarter share count